JVCKENWOOD we are proceeding with the application of Gazefinder, a gaze tracking and measuring system developed by leveraging our visual and optical technologies that we have cultivated thus far, for medical equipment. Gazefinder enables accurate measurement of the examinee’s line of sight, i.e. the points on the monitor screen that the examinee is looking at. Gaze is closely related to brain activity and gaze measurement enables objective and quantitative assessment of the development of the brain and detection of brain diseases, disorders, etc.
Contributing to the early detection of autism spectrum disorder (ASD)
One expected use of Gazefinder is to support the diagnosis of autism spectrum disorder, which even among developmental disorders is known for involving particular difficulty in communication.
During childhood, lower grade students explicitly demonstrate their difficulty in studying and behavioral aspects, while for higher grade students various complications arise and become hard to find. Therefore, it is important to identify the symptoms and respond at an early stage. (Source: Materials from the Reporting Meeting of Elementary and Secondary Education Bureau of the Ministry of Education, Culture, Sports, Science and Technology, February 2016)
Appropriate diagnoses help to ensure the provision of proper support in educational environments, and to promote the understanding of the people around children with disorders. In addition, early diagnosis makes it possible to provide the necessary support from the time of infancy, which has been proven to be significantly useful for improving a child’s ability to attend regular classes. We therefore recognize that the more children that receive early treatment via the diagnosis support of Gazefinder, the greater the likelihood of leading those children to engage with society in the future.
We are conducting clinical trials in Japan and Australia with an eye to obtaining certification for Gazefinder as a supplementary medical device aiding the diagnosis of autism spectrum disorder(ASD). (Completed clinical trials in Australia in October 2021) Once medical device certification is granted, the Gazefinder will add an objective assessment to a physician’s diagnosis, enhancing the acceptance and understanding of persons raising children with ASD and promoting earlier access to clinical intervention to improve the prognosis of children with ASD.
Also applied to early diagnosis of dementia patients
Gazefinder is expected to be applied to early diagnosis of dementia patients, who will presumably further increase. As simplified and precise diagnosis systems for dementia are required, Gazefinder is a product which can meet this need. JVCKENWOOD worked with a group of researchers at the Osaka University Graduate School of Medicine to jointly develop a new cognitive assessment technique. A quick assessment technique that requires virtually no written or verbal instructions, not only it imposes very little burden on subjects but also can be marketed globally. When tested with 80 subjects at Osaka University Hospital, the assessment technique demonstrated a high correlation with the existing standard cognitive testing method in which the doctor spends about 20 minutes questioning the patient. The findings of this study have been published by Osaka University and made available to the public on Scientific Reports, an online British scientific journal (link to Scientific Reports). Gazefinder minimizes the mental and physical burden during examination and accurately finds out risks of dementia. It then helps encourage early and proper treatment as well as a supporting environment, contributing to reducing the burden of both the patients and their families. As the utilization of Gazefinder advances, we anticipate that we can help solve significant issues related to medical care for seniors, such as dementia and medical expenses.